Hematologic Malignancies CME

Tell us what you think about Healio

Sign in for a personal experience.

Customized content served to meet your interests.

Register for Healio to get content tailored to your specialty and areas of interest. It’s FREE and only takes one minute. Register now!

CME
Debate: “Interferon Sensitivity”: Adjuvant IFN Should Be Used Only in Patients with Ulceration and/or Microscopic Nodal Disease
May 2, 2013
This activity will feature two experts debating the efficacy of high-dose, intermediate-dose and low-dose interferon in melanoma patients in various disease stages and with certain characteristics,… More »
This activity is supported by educational grants from Bristol-Myers Squibb, Delcath Systems, Inc., Merck & Co., Inc., OncoSec Medical, Inc., Prometheus and Provectus Pharmaceuticals, Inc.
Credit Type(s): CME | Credit: 0.5

CME
Does Biochemotherapy Have a Role in Adjuvant Therapy?
May 2, 2013
This activity will discuss the role of biochemotherapy in adjuvant therapy when treating high-risk melanoma patients… More »
This activity is supported by educational grants from Bristol-Myers Squibb, Delcath Systems, Inc., Merck & Co., Inc., OncoSec Medical, Inc., Prometheus and Provectus Pharmaceuticals, Inc.
Credit Type(s): CME | Credit: 0.25

CME
Current Status of Injectable Therapy
April 9, 2013
This activity will review intralesional therapies, both those available and in development; discuss response rates to intralesional therapies; discuss adverse reactions to intralesional therapies;… More »
This activity is supported by educational grants from Bristol-Myers Squibb, Delcath Systems, Inc., Merck & Co., Inc., OncoSec Medical, Inc., Prometheus and Provectus Pharmaceuticals, Inc.
Credit Type(s): CME | Credit: 0.5

Hematology/Oncology